NDLI: Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach

Content Provider	PubMed Central
Author	Binaschi, Monica Simonelli, Cecilia Cristina, Goso Mario, Bigioni Maggi, Carlo Alberto
Copyright Year	2011
Abstract	Ovarian cancer has the highest mortality rate among gynaecological tumours despite the fact that the majority of patients with advanced disease achieve complete remission after first-line surgery and chemotherapy. Unfortunately, disease recurrence occurs in the majority of patients and second-line treatments are not curative. Clearly, the persistence of dormant and drug-resistant cells after front-line treatments results in the inability to cure the disease. The identification of cancer-initiating cells or cancer stem cells as key players in the development of recurrence has opened up a novel field of research aimed at identifying additional innovative therapeutic approaches. Strategies of maintenance therapy to extend the survival of patients have been studied, but to date no overall survival benefit has been detected. Currently, numerous clinical trials have just been completed or are ongoing involving patients achieving a complete clinical response after first-line chemotherapy in order to evaluate the efficacy of different therapeutic approaches in terms of disease-free survival and overall survival. At the 2010 ASCO meeting, the first positive results of a phase III clinical trial in this setting were presented: bevacizumab (15 mg/kg i.v. every 21 days) added to first-line chemotherapy and continued for an additional 15 cycles was found to prolong progression-free survival of 3.8 months in comparison to 6 cycles of chemotherapy alone or only 6 cycles of chemotherapy plus bevacizumab. In addition, positive results were announced for a second phase III trial testing bevacizumab in the same setting, but at half dose. The final assessment of the overall clinical benefit and the approval of bevacizumab in maintenance therapy by regulatory agencies is expected to be positive, as are the final results of abagovomab phase III trial MIMOSA, another antibody-based therapy tested as a maintenance treatment for advanced ovarian cancer patients. Encouraging preliminary results confirming the safety profile and the immunogenic activity of abagovomab were presented at the last ASCO meeting. The final results are expected to be released in the first half of 2011.
Related Links	http://dx.doi.org/10.3892/etm.2011.192
Starting Page	173
File Format	PDF
ISSN	17920981
e-ISSN	17921015
Journal	Experimental and Therapeutic Medicine
Issue Number	2
Volume Number	2
Language	English
Publisher	D.A. Spandidos
Publisher Date	2011-03-01
Access Restriction	Open
Rights Holder	D.A. Spandidos
Subject Keyword	Immunology and Microbiology (miscellaneous) Cancer Research Medicine(all) Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research 2400/2401

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Methylation of tumor suppressor genes in ovarian cancer

Downregulation of telomerase maintenance-related ACD expression in patients undergoing immunosuppresive therapy following kidney transplantation

Genetically modified T cells in cancer therapy: opportunities and challenges

Fishing for the genetic basis of cardiovascular disease

From fish tank to bedside in cancer therapy: an interview with Leonard Zon

Prognostic significance of the mitochondrial scoring system in ovarian cancer

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis

Cyclin D1 predicts the prognosis of advanced serous ovarian cancer

Gene expression patterns in the histopathological classification of epithelial ovarian cancer

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach

Similar Documents

Methylation of tumor suppressor genes in ovarian cancer

Downregulation of telomerase maintenance-related ACD expression in patients undergoing immunosuppresive therapy following kidney transplantation

Genetically modified T cells in cancer therapy: opportunities and challenges

Fishing for the genetic basis of cardiovascular disease

From fish tank to bedside in cancer therapy: an interview with Leonard Zon

Prognostic significance of the mitochondrial scoring system in ovarian cancer

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis

Cyclin D1 predicts the prognosis of advanced serous ovarian cancer

Gene expression patterns in the histopathological classification of epithelial ovarian cancer

Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach